GlassScriptPhysician profile
Clint D Kingsley
NPI 1053348037
$11,969.55
in general payments reported to CMS, 2019-2025
66 companies · $3,255 in 2025
The $3,255 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $166 · 2021: $134 · 2022: $1,955 · 2023: $2,590 · 2024: $3,454 · 2025: $3,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,179 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,179.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,237.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $893.77 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $848.51 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $693.39 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Pfizer INC. | $599.41 | 2019-2025 | |
| Seagen INC. | $504.70 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $479.46 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $469.30 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $358.00 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Exelixis INC. | $302.23 | 2022-2025 | Cabometyx |
| Abbvie INC. | $289.36 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.54 | 2020-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genzyme Corporation | $278.75 | 2023-2025 | |
| Celgene Corporation | $278.01 | 2023-2025 | Reblozyl, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $219.10 | 2022-2023 | Imbruvica, Epkinly |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $219.07 | 2022-2025 | Soliris, Ultomiris |
| Regeneron Healthcare Solutions, INC. | $215.83 | 2021-2025 | Libtayo |
| Eisai INC. | $206.33 | 2021-2024 | |
| Daiichi Sankyo INC. | $204.05 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Amgen INC. | $199.86 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Lilly USA, LLC | $194.45 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $194.35 | 2022-2025 | |
| Beone Medicines USA, INC. | $185.58 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $164.60 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $141.33 | 2022-2024 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $139.82 | 2024 | Orserdu |
| Astellas Pharma US INC | $132.37 | 2024-2025 | Xtandi |
| Tersera Therapeutics LLC | $125.58 | 2022-2024 | Zoladex, Xermelo |
| Array Biopharma INC | $119.55 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $112.68 | 2019-2024 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.35 | 2022-2025 | Gilotrif |
| Sobi, INC | $92.37 | 2024-2025 | |
| Blueprint Medicines Corporation | $89.43 | 2022-2024 | Ayvakit |
| Kite Pharma, INC. | $88.27 | 2022-2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $82.28 | 2023-2025 | Fotivda |
| Pharmaessentia USA Corporation | $80.61 | 2023-2025 | Besremi |
| Springworks Therapeutics, INC. | $76.62 | 2024-2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $75.78 | 2023-2025 | |
| Adc Therapeutics America, INC. | $71.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $69.80 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Coherus Oncology, INC. | $67.29 | 2022-2025 | Loqtorzi |
| Rigel Pharmaceuticals, INC. | $61.32 | 2022-2024 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $60.87 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $55.11 | 2023-2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $51.29 | 2023-2025 | Qinlock |
| Puma Biotechnology, INC. | $50.86 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $50.74 | 2022-2024 | Xpovio |
| Adaptive Biotechnologies Corporation | $46.66 | 2024 | Clonoseq |
| Iovance Biotherapeutics, INC. | $46.49 | 2024-2025 | Amtagvi |
| Kyowa Kirin, INC. | $41.27 | 2025 | |
| Geron Corporation | $41.09 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $38.38 | 2023-2025 | Sylvant, Enjaymo |
| Agios Pharmaceuticals, INC. | $36.36 | 2024-2025 | Pyrukynd |
| Genmab U.S., INC. | $35.58 | 2023-2024 | Epkinly |
| Dendreon Pharmaceuticals LLC | $24.95 | 2023 | Provenge |
| Jazz Pharmaceuticals INC. | $22.72 | 2025 | |
| Shield Therapeutics INC | $20.40 | 2024 | |
| Novocure INC. | $19.09 | 2021 | |
| Global Blood Therapeutics, INC. | $17.16 | 2022 | |
| Acrotech Biopharma INC. | $16.83 | 2024 | Beleodaq |
| Verity Pharmaceuticals INC. | $14.50 | 2023 | Trelstar |
| Fennec Pharmaceuticals, INC. | $14.37 | 2025 | Fyarro |
| Myriad Genetic Laboratories, INC. | $11.58 | 2022 | |
| Emd Serono, INC. | $11.25 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,598.65 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Kingsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.